X4 Pharmaceuticals Inc [NASDAQ: XFOR] price surged by 38.91 percent to reach at $0.23.
The one-year XFOR stock forecast points to a potential upside of 73.44. The average equity rating for XFOR stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on X4 Pharmaceuticals Inc [XFOR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XFOR shares is $3.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XFOR stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for X4 Pharmaceuticals Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 12, 2023. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on August 30, 2023, representing the official price target for X4 Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $3, while Cantor Fitzgerald analysts kept a Overweight rating on XFOR stock.
The Average True Range (ATR) for X4 Pharmaceuticals Inc is set at 0.11, with the Price to Sales ratio for XFOR stock in the period of the last 12 months amounting to 122.69. The Price to Book ratio for the last quarter was 2.28, with the Price to Cash per share for the same quarter was set at 0.79.
XFOR Stock Performance Analysis:
X4 Pharmaceuticals Inc [XFOR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.67. With this latest performance, XFOR shares gained by 140.08% in over the last four-week period, additionally plugging by 20.24% over the last 6 months – not to mention a drop of -4.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XFOR stock in for the last two-week period is set at 65.16, with the RSI for the last a single of trading hit 68.93, and the three-weeks RSI is set at 62.24 for X4 Pharmaceuticals Inc [XFOR]. The present Moving Average for the last 50 days of trading for this stock 0.5083, while it was recorded at 0.6363 for the last single week of trading, and 0.7942 for the last 200 days.
Insight into X4 Pharmaceuticals Inc Fundamentals:
X4 Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.89.
X4 Pharmaceuticals Inc [XFOR] Institutonal Ownership Details
There are presently around $67.66%, or 68.45%% of XFOR stock, in the hands of institutional investors. The top three institutional holders of XFOR stocks are: BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with ownership of 16.92 million shares, which is approximately 8.4582%. NEA MANAGEMENT COMPANY, LLC, holding 14.99 million shares of the stock with an approximate value of $$8.69 million in XFOR stocks shares; and NEA MANAGEMENT COMPANY, LLC, currently with $$6.19 million in XFOR stock with ownership which is approximately 5.3382%.
